{"id":66230,"date":"2026-01-31T15:34:07","date_gmt":"2026-01-31T21:34:07","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=66230"},"modified":"2026-01-31T15:34:07","modified_gmt":"2026-01-31T21:34:07","slug":"wegovy-weight-loss-results-what-the-data-shows","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/wegovy-weight-loss-results-what-the-data-shows\/","title":{"rendered":"Wegovy Weight Loss Results: What the Data Shows"},"content":{"rendered":"

Wegovy (semaglutide 2.4 mg) produces average weight loss of 15% of body weight over 68 weeks, according to clinical trial data. In the landmark STEP 1 trial, 86% of participants lost at least 5% of their body weight, 69% lost at least 10%, and about half achieved weight loss of 15% or more. Beyond weight loss, the SELECT trial demonstrated a 20% reduction in major cardiovascular events like heart attacks and strokes, making Wegovy the first weight loss medication proven to reduce cardiovascular risk.<\/p>\n

These results represent some of the most significant outcomes ever seen with a weight loss medication. But averages only tell part of the story. Let’s examine what the research actually shows and what you can realistically expect.<\/p>\n

The STEP Trials: The Foundation of Wegovy’s Approval<\/h2>\n

Wegovy’s FDA approval was based primarily on the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. These large scale studies tested semaglutide 2.4 mg in thousands of participants across different populations and conditions.<\/p>\n

The STEP 1 trial<\/a>, published in the New England Journal of Medicine, enrolled nearly 2,000 adults with obesity or overweight (with at least one weight related condition) who did not have diabetes. Participants received either semaglutide 2.4 mg weekly or placebo, along with lifestyle counseling.<\/p>\n

After 68 weeks, the results were striking:<\/p>\n

\n\n\n\n\n\n\n\n\n\n
Outcome<\/th>\nSemaglutide Group<\/th>\nPlacebo Group<\/th>\n<\/tr>\n<\/thead>\n
Average weight loss<\/td>\n14.9%<\/td>\n2.4%<\/td>\n<\/tr>\n
Lost at least 5%<\/td>\n86%<\/td>\n32%<\/td>\n<\/tr>\n
Lost at least 10%<\/td>\n69%<\/td>\n12%<\/td>\n<\/tr>\n
Lost at least 15%<\/td>\n50%<\/td>\n5%<\/td>\n<\/tr>\n
Lost at least 20%<\/td>\n32%<\/td>\n2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

The treatment difference of 12.4 percentage points represents the medication’s effect beyond what lifestyle changes alone produce. This gap is larger than any previously approved weight loss medication.<\/p>\n

Long Term Results: The STEP 5 Trial<\/h2>\n

One question about any weight loss intervention is whether results last. The STEP 5 trial<\/a> followed participants for two full years to answer this question.<\/p>\n

At 104 weeks, participants taking semaglutide had lost an average of 15.2% of their body weight, compared to 2.6% with placebo. Importantly, weight loss achieved by week 52 was maintained through week 104, suggesting that continued treatment prevents regain.<\/p>\n

The breakdown of results at two years:<\/p>\n